NCT00139867
Completed
Phase 3
A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
ConditionsParkinson's Disease
DrugsPARCOPA
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Parkinson's Disease
- Sponsor
- UCB Pharma
- Locations
- 1
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.
Detailed Description
See approved Package Insert for Adverse Event information.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Stable Parkinson's Disease
Exclusion Criteria
- •Not using carbidopa/levodopa tablets
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT04179032GlaxoSmithKline25
Completed
Phase 3
CORAL XT - Open-label Extension Trial of the CORAL TrialPainNeoplasmsChronic PainNCT02031432Tris Pharma, Inc.76
Completed
Phase 1
An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)InfertilityNCT00647933Organon and Co24
Terminated
Phase 3
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson DiseaseNCT05047523Alexion Pharmaceuticals, Inc.40
Recruiting
Phase 2
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusNCT06563817Beijing Tiantan Hospital53